Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2026

Genmab — Januar 2026

Planlagt Fastgjort Låst Flyttet Genmab
295 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Raun
    wrote on sidst redigeret af
    #267

    Det ligner en af de dage, hvor US af en eller anden grund handler aktien op

    1 Reply Last reply
    0
    • nohopeN Offline
      nohopeN Offline
      nohope
      wrote on sidst redigeret af
      #268

      26/1 "Genmab halts enrollment for cancer drug from ProfoundBio buyout" Ingen der har kommentarer til dette ?

      1 Reply Last reply
      0
      • R Offline
        R Offline
        Raun
        wrote on sidst redigeret af
        #269

        Er det ikke samme emne @bb8 havde i aftes?

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #270

          Det må vist betegnes som forventet. Meget lille studie på 4 klinikker og på ingen måde en vigtig del af baggrunden for købet.

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #271

            Kan såmænd lige så godt være et positivt tegn på, at de har noget andet og bedre inden for samme område, hvis man endelig vil lægge noget i det ...

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #272

              The news is 2 weeks old. We’ll hear at some point what the exact reason is, but my guess is that they will go with ‘portfolio prioritisation’ 😉

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #273

                EGFR x c-MET is already a crowded space and Genmab now also have MCLA-129 from Merus, an EGFRxc-MET Biclonics. Not sure they are going to keep that one, as the tox profile is not great, but it is a large trial that has been going since 2021, so i think we can expect a decision soon after Genmab fully takes control at Merus.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #274

                  For me the most interesting is that they just opened a new Petosemtamab trial in NSCLC. We have not seen NSCLC data in public yet i believe, but Genmab will have seen it. Timing coincides. My best guess at this moment would be that Genmab goes with Peto for lung cancer.

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #275

                    Could very well be it.

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #276

                      Hope they will tell something about it along with the annual report.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #277

                        FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          JKY_VH
                          wrote on sidst redigeret af
                          #278

                          Tak E L:-)

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #279

                            Genmabs Darzalex Faspro godkendt til kombinationsbehandling af myelomatose https://proinvestor.com/investornyt/1407741/genmabs-darzalex-faspro-godkendt-til-kombinationsbehandling-af-myelomatose

                            1 Reply Last reply
                            0
                            • W Offline
                              W Offline
                              w
                              wrote on sidst redigeret af
                              #280

                              hvad er dagens problem?

                              1 Reply Last reply
                              0
                              • nohopeN Offline
                                nohopeN Offline
                                nohope
                                wrote on sidst redigeret af
                                #281

                                Tror jeg dropper aktier og går over til Lotto. Lotto virker mere forudsigeligt.

                                1 Reply Last reply
                                0
                                • W Offline
                                  W Offline
                                  w
                                  wrote on sidst redigeret af
                                  #282

                                  har du de fire første tal til
                                  aftenens trækning?

                                  1 Reply Last reply
                                  0
                                  • R Offline
                                    R Offline
                                    Raun
                                    wrote on sidst redigeret af
                                    #283

                                    Vi har set dette scenarie så mange gange efterhånden. Så absolut ingen overraskelse her. - aktien er styret og absolut ikke modtagelig for TA

                                    1 Reply Last reply
                                    0
                                    • concilladoC Offline
                                      concilladoC Offline
                                      concillado
                                      wrote on sidst redigeret af
                                      #284

                                      Enig. En hurtig gevinsthjemtagning og mulighed for supplering, når den ryger tilpas ned i bunden af kanalen (igen-igen).

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #285

                                        on the EGFR x cMet crowded space - Two more companies try to outdo Rybrevant https://www.oncologypipeline.com/apexonco/two-more-companies-try-outdo-rybrevant

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #286

                                          H.C. Wainwright has reiterated a Buy rating and $39.00 price target on Genmab A/S (NASDAQ:GMAB) following FDA approval of DARZALEX FASPRO for newly-diagnosed multiple myeloma patients.
                                          https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-genmab-stock-at-39-price-target-93CH-4469885

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper